GlassScriptPhysician profile
Stephen M Olmstead
NPI 1346298890
$8,867.35
in general payments reported to CMS, 2019-2025
34 companies · $2,426 in 2025
The $2,426 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $745 · 2021: $914 · 2022: $845 · 2023: $1,222 · 2024: $1,832 · 2025: $2,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,429 · Education: $50.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,428.71 |
| Education | $50.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,675.85 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,056.38 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $989.67 | 2019-2025 | |
| Genzyme Corporation | $691.03 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $546.49 | 2020-2025 | Takhzyro, Cuvitru |
| Glaxosmithkline, LLC. | $497.13 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Csl Behring | $420.02 | 2019-2025 | Andembry, Haegarda |
| Grifols USA, LLC | $415.02 | 2020-2025 | Xembify, Gamunex-C |
| Blueprint Medicines Corporation | $404.22 | 2024-2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $329.33 | 2019-2022 | |
| Genentech USA, INC. | $241.97 | 2019-2025 | Xolair |
| Amgen INC. | $225.20 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.06 | 2019-2022 | |
| Alk-Abello, INC | $156.49 | 2019-2022 | |
| Optinose US, INC. | $153.50 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $123.11 | 2025 | Ebglyss |
| Shire North American Group INC | $117.45 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $92.22 | 2025 | Neffy |
| Pfizer INC. | $82.08 | 2020-2025 | |
| Biocryst US Sales Co., LLC | $67.67 | 2023-2024 | Orladeyo |
| Kaleo, INC. | $55.19 | 2023 | Auvi-Q |
| Pharming Healthcare, INC. | $53.37 | 2025 | Ruconest |
| Hikma Pharmaceuticals USA | $50.97 | 2023-2024 | Ryaltris |
| Galderma Laboratories, L.P. | $44.57 | 2025 | Nemluvio |
| Organon LLC | $34.79 | 2025 | Vtama |
| Hospira, INC. | $31.59 | 2024-2025 | |
| Octapharma USA, INC. | $28.55 | 2022 | |
| Incyte Corporation | $25.37 | 2025 | Opzelura |
| Azurity Pharmaceuticals, INC. | $22.31 | 2025 | Alvesco |
| Novo Nordisk INC | $19.94 | 2023 | Ozempic |
| Leo Pharma INC. | $15.03 | 2025 | Adbry |
| Teva Pharmaceuticals USA, INC. | $12.84 | 2020 | |
| Merck Sharp & Dohme LLC | $12.50 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Olmstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.